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Abstract In type 2 diabetes mellitus, glucose homeosta-
sis is tightly maintained through insulin secretion and
insulin sensitivity. Therefore, ﬁnding an accurate method
to assess insulin secretion and sensitivity using clinically
available data would enhance the quality of diabetic
medical care. In an effort to ﬁnd such a method, we
developed a computational approach to derive indices of
these factors using a 2-h oral glucose tolerance test
(OGTT). To evaluate our method, clinical data from sub-
jects who received an OGTT and a glucose clamp test were
examined. Our insulin secretion index was signiﬁcantly
correlated with an analogous index obtained from a
hyperglycemic clamp test (r = 0.90, n = 46, p\0.001).
Our insulin sensitivity index sensitivity was also
signiﬁcantly correlated with an analogous index obtained
from a hyperinsulinemic-euglycemic clamp test (r = 0.56,
n = 79, p\0.001). These results suggest that our method
can potentially provide an accurate and convenient tool
toward improving the management of diabetes in clinical
practice by assessing insulin secretion and insulin
sensitivity.
Keywords Insulin secretion   Insulin sensitivity   Type 2
diabetes   Mathematical model   OGTT   Clinical use
Introduction
Insulin secretion and insulin sensitivity play a crucial role
in glucose homeostasis; hence, assessing these factors in
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DOI 10.1007/s12576-011-0153-zthe care of type 2 diabetes (T2D) is important. The
deregulation of these factors, which results in insufﬁcient
insulin secretion and activity, leads to hyperglycemia [1];
therefore, insulin secretion and insulin sensitivity are tar-
geted by therapies for the treatment of diabetes [2].
Many mathematical models have been proposed for the
assessment of insulin secretion and insulin sensitivity [3]
by analyzing glucose tolerance tests such as the intrave-
nous glucose tolerance test (IVGTT) and the oral glucose
tolerance test (OGTT). Among these approaches, the
minimal model proposed by Bergman et al. [4], which
analyzes an IVGTT to assess insulin sensitivity, is one of
the most notable. To introduce this concept into more
general practice, several other models that use an OGTT
have been reported. For example, mathematical models to
analyze 11 blood samples obtained during a 5-h OGTT
have been proposed and validated by comparison with
direct measurement methods. The second-phase (or static)
insulin secretion index proposed by Toffolo et al. [5] has
been validated using a glucose clamp method [6], and the
insulin sensitivity index proposed by Dalla Man et al. [7]
has been validated using a glucose tracer method [8].
Modeling techniques that rely on data from a more
convenient OGTT protocol, while maintaining reasonable
assessment accuracy, would have a greater chance of
application in clinical settings [9]. In particular, test results
from 2-h OGTTs would be beneﬁcial because the 2-h
glucose level during an OGTT has been used as one of the
diagnostic criteria for diabetes by the World Health
Organization (WHO) [10].
The purpose of this study was to provide an accurate
method for assessing insulin secretion and insulin sensi-
tivity in T2D from clinically available data. For this pur-
pose, we developed a computational method to assess these
factors using only four blood samples obtained during a 2-h
OGTT. The method is based on mathematical modeling
combined with extrapolation and interpolation methods.
Our indices for measuring insulin secretion and insulin
sensitivity using OGTTs were compared with analogous
indices obtained using a glucose clamp technique [11]i n
Japanese subjects with varying degrees of glucose
tolerance.
Methods
Mathematical modeling
We considered plasma glucose and insulin levels to be the
two major variables for this analysis; therefore, our math-
ematical model uses these variables only.
Oral glucose is absorbed from the intestines and passes
through the liver before entering the systemic circulation.
The liver functions as a buffer that keeps the glucose level
stable by suppressing splanchnic glucose output (SGO) to
the circulatory system. Therefore, to construct a model for
interpreting OGTT results, a description of liver function is
required.
The challenge in constructing our OGTT model was to
develop a parametric description of SGO that reﬂects liver
function. To describe SGO, a new function was introduced
in our model. We adapted well-validated and reported
models for the other aspects of functions.
Model to derive the insulin sensitivity index
Intravenously administered glucose circulates throughout
the body immediately after ingestion. However, orally
administered glucose is absorbed from the intestines and
ﬁrst passes through the liver before entering the systemic
circulation. This ﬁrst-pass effect of the liver must be con-
sidered in a model that assesses insulin sensitivity using
OGTTs. For this reason, SGO was incorporated into our
model. A function, RDSGO, that represents the varying rate
of SGO was introduced and coupled with the classical
minimal model, which describes glucose kinetics without
SGO and is applicable to IVGTT studies [4]. The general
formulation is described as follows:
dG
dt
¼  ð pG1 þ XÞG þ pG1Gð0Þ þ RDSGO
dX
dt
¼  pG2X þ pG3ðI   Ið0ÞÞ;
where G (mg dl
-1) is the plasma glucose concentration,
I (lUm l
-1) is the plasma insulin concentration, X (min
-1)
is a variable in a remote insulin compartment where insulin
is active in accelerating glucose disappearance, RDSGO
(mg dl
-1 min
-1) is the varying SGO rate after an oral
glucose load, and pG1 (min
-1), pG2 (min
-1), and pG3
(lU
-1 ml min
-2) are rate parameters. A subscript in
parentheses represents a value at a time after the oral
glucose load, and a zero subscript (e.g., I(0) and G(0)) rep-
resents a value at time 0. By deﬁning insulin sensitivity as
the quantitative inﬂuence of insulin on increasing the dis-
appearance of glucose, the insulin sensitivity index is
deductively given by pG3/pG2. The explicit deﬁnition of X,
the parameters, and the derivation of the index are found in
reference [4].
In healthy subjects, SGO is maintained within a low
range by a prompt increase in glucose uptake and a
suppression of glucose production. In T2D, some of
these functions are disordered, and these dysfunctions
contribute to hyperglycemia [12–16]. It is known that
insulin is one of the key factors responsible for the
hepatic functions of glucose uptake and suppression;
however, there are other key factors involved, such as
322 J Physiol Sci (2011) 61:321–330
123the portal signal (the difference in glucose concentration
between the portal vein and the hepatic artery), whose
regulatory mechanisms have not yet been clearly deﬁned
[12–16]. As was mentioned, the present requirement is
not to describe the details of hepatic glucose regulation
but to describe SGO. After that is done, we can model
RDSGO to satisfy the following relation between the state
of hepatic function and SGO. In T2D (in which there is
dysfunction in hepatic glucose regulation), the increase
in the SGO rate is assumed to be larger because the
increase in hepatic glucose uptake and suppression of
hepatic glucose production are smaller than in healthy
subjects. Thus, we assumed that the maximum value for
SGO is larger, and that peak SGO occurs earlier in T2D.
Most of the oral glucose absorbed from the intestines
appears in the plasma within 2 or 3 h after administra-
tion [16]. For this reason, SGO returns to basal levels
regardless of the state of hepatic glucose function (i.e.,
RDSGO converges to within a small and narrow range
after 2 h). We modeled RDSGO to satisfy the above
requirements for peak value, peak time, and convergence
of SGO. RDSGO is deﬁned by the following equation:
RDSGO ¼
1
kwW
1
pG4pG5
fwðt;pG4;pG5Þ;
where fwðt;a;bÞ¼
btb 1
ab exp  
tb
ab
  
:
kW (kg
-1 min
-1 mg
-1 dl) is a constant, W (kg) is the
weight, the parameter a (min) is the scale parameter, the
parameter b (dimensionless) is the shape parameter, and fw
(min
-1) is the Weibull density function [17]. In
pharmacokinetics, this density function is widely used to
describe drug absorption following oral administration. As
long as the two parameters a and b are positive, the area
under the glucose absorption curve (AUC) will increase
exponentially with time and asymptotically approach 1 as
time approaches inﬁnity. To satisfy the assumptions about
SGO, fw is multiplied by the inverse of pG4 and pG5 in the
expression for RDSGO. The expression thus deﬁned satisﬁes
the assumptions and can describe a wide variety of SGO
functions (Figs. 1, 2).
Model to derive the insulin secretion index
Pancreatic insulin secretion (RI) can be described as the
sum of two components: dynamic insulin secretion (RI1)
and static insulin secretion (RI2). This sum is based on a
previously reported OGTT minimal model [5]. The rate of
change in plasma insulin concentration (dI/dt) is repre-
sented by the sum of RI, and the insulin circulation rate is
calculated from a single-compartment model with a rate
parameter pI1 (min
-1) for insulin disappearance,
RI ¼ RI1 þ RI2
dI
dt
¼  pI1ðI   Ið0ÞÞþRI:
RI1 (lUm l
-1 min
-1) represents the secretion of rapidly
releasable insulin stored in b-cells in response to elevations
in the glucose level, according to the following equation:
RI1 ¼
pI2
dG
dt if dG
dt [0
0i f dG
dt  0
(
;
where the parameter pI2 (lUm l
-1 mg
-1 dl) describes the
sensitivity of dynamic insulin secretion by the b-cells.
RI2 (lUm l
-1 min
-1) represents the secretion of newly
recruited insulin in response to an elevated glucose level,
according to the following equation (with RIb = 0):
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Fig. 2 Max values of 1
pG4pG5 ðfwt;pG4;pG5Þ: The ranges of the param-
eters are from 50 to 300 (min) for pG4 and from 1 to 3 (dimensionless)
for pG5
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123dRI2
dt
¼
  1
pI3 fRI2   pI4ðG   Gð0ÞÞg if G   Gð0Þ [0
  1
pI3 RI2 if G   Gð0Þ  0
(
:
The parameter pI4 (lUm l
-1 mg
-1 dl min
-1) describes
the sensitivity of static insulin secretion by b-cells to an
elevated glucose level with a time constant parameter pI3
(min).
RI is always non-negative, and when RI1 þ RI2\0;
RI ¼ 0:
Clinical data collection
To evaluate our insulin secretion index, we retrospectively
studied 46 Japanese subjects who had received an OGTT
and a hyperglycemic clamp (HGC) within 1 week of each
other. The subjects had the following characteristics: 33
male, 13 female; 50.4 ± 12.0 (mean ± SD) years old;
body mass index (BMI) 26.2 ± 6.1 kg m
-2; and 9 with
normal glucose tolerance (NGT), 5 with impaired glucose
tolerance (IGT), and 32 with T2D. To evaluate our insulin
sensitivity index, we retrospectively studied 82 Japanese
subjects who had received an OGTT and a hyper-
insulinemic-euglycemic clamp (HIC) within 1 week of
each other. These subjects had the following characteris-
tics: 79 subjects after exclusions; 57 male, 22 female;
53.1 ± 13.4 years old; BMI 25.6 ± 5.1 kg m
-2; and 10
with NGT, 11 with IGT, and 58 with T2D. To assess
insulin sensitivity in all areas other than the liver in the
HIC, the insulin infusion rate was adjusted to achieve a
serum insulin concentration of 100 lUm l
-1; because of
the possibility of insufﬁcient inhibition of hepatic glucose
production, we eliminated 3 cases with a steady-state
insulin concentration under 50 lUm l
-1 during the HIC
[12]. Clinical and metabolic characteristics are summarized
in Table 1. All of these clinical tests were performed at the
Osaka University Graduate School of Medicine (46 cases)
or the Kobe University Graduate School of Medicine (36
cases).
The clinical protocol was approved by the ethics com-
mittee of each institution, and written informed consent
was obtained from all subjects.
For the OGTTs, the standard WHO procedures were
followed [10]. In brief, after a 12-h overnight fast, 75 g of
glucose was given orally. Blood samples were collected at
0, 30, 60, and 120 min after the ingestion of the glucose,
and the plasma glucose and serum insulin concentrations
were measured.
For the glucose clamp methods, after a 12-h overnight
fast, and before the start of the HGC or HIC, an artiﬁcial
pancreas was used. An intravenous line was inserted into
an antecubital vein for glucose and insulin administration.
A second intravenous line was inserted into a vein in the
contralateral hand for blood collection. During the clamp,
blood samples were collected at 1- to 10-min intervals, and
plasma glucose and serum insulin concentrations were
measured.
For the HGC, exogenous glucose was infused intrave-
nously by automatically adjusting the infusion rate to attain
a plasma glucose concentration of 200 mg dl
-1 for 90 min.
All of the HGCs were performed at Osaka University.
For the HIC, the infusion rate of regular insulin was
ﬁxed at 1.1 mU kg
-1min
-1 to attain a serum insulin con-
centration of 100 lUm l
-1, and exogenous glucose was
infused to maintain a plasma glucose concentration of
90 mg dl
-1 for at least 90 min.
The plasma glucose concentrations were determined
using the glucose oxidase method. The serum insulin
concentrations were determined using a sandwich enzyme
immunoassay system. Spherelight Insulin (Sanyo Chemi-
cal Industries Ltd., Japan) was used at the Osaka Uni-
versity Graduate School of Medicine for insulin
measurement. E-test Tosoh II (IRI) (Tosoh Co., Japan)
was used at the Kobe University Graduate School of
Medicine. An artiﬁcial endocrine pancreas (STG-22;
Nikkiso Co., Japan) was used for the glucose clamp
studies. The tested values were properly calibrated by
each facility.
Individual parameter estimation from OGTT data
To estimate the parameters in the OGTT model, the ref-
erence values for the model input were extrapolated and
interpolated from the observed glucose and insulin values.
The glucose and insulin values at 300 min were assumed to
have returned to the baseline levels, based on results
reported from 5-h OGTTs [9, 18]. The values at 180 min
were extrapolated from those at 0, 30, 60, and 120 min
using a support vector machine [19] and following a pre-
viously reported procedure [20]. For this interpolation, a
piecewise cubic Hermite interpolation [21, 22] was used as
one of the interpolation methods. This method generates a
curve which passes through the input values and does not
overshoot between them. The parameters related to insulin
secretion (pI) were estimated by minimizing the residual
sum of squares of the insulin level between the reference
and the model. The parameters related to glucose metab-
olism (pG) were estimated by minimizing the residual sum
of glucose levels between the reference and the model. The
parameter sets of pI and pG were independently estimated.
The dG/dt and dI/dt were calculated by the interpolated
functions. A brute-force algorithm was used to estimate
them. This parameter estimation did not require a speciﬁc
optimization algorithm, and comparable parameters can be
obtained using other approaches, such as a genetic
algorithm.
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123The parameters estimated for the individual cases were
pG3, pG4, pG5, pI2, pI3, and pI4. The ranges for the estimated
parameters were from 0.02 to 40 (lU
-1 ml min
-2 10
-6)
for pG3, from 50 to 300 (min) for pG4, from 1 to 3
(dimensionless) for pG5, from 0 to 80 (lUm l
-1 mg
-1 dl)
for pI2, from 1 to 300 (min) for pI3, and from 0 to 600
(lUm l
-1 mg
-1 dl min
-1) for pI4.
The other parameters were ﬁxed to the mean population
values found in the literature. The constant kW used in the
RDSGO equation was set using the results of a direct SGO
measurement that utilized a glucose tracer approach during
an OGTT. The values and sources were as follows:
pG1 = 0.014 (min
-1)[ 7, 23], pG2 = 0.012 (min
-1)[ 8],
pI1 = 0.19 (min
-1)[ 24], and kW = 2.0 (kg
-1 mg
-1
dl min
-1 10
-7)[ 16].
The parameters estimated for the individual cases were
selected on the basis of their usefulness for assessing the
pathophysiology underlying T2D. Other parameters that
were ﬁxed as constants in the model can have individual
variation, which could have affected the results of the
OGTT. However, we focused on the selected parameters in
the present study.
Derivation and evaluation of clinical indices from our
method
The steady-state serum insulin concentration during the
HGC (SSIHGC) was used as an estimate of the second-
phase insulin secretion in response to elevated glucose. The
steady-state glucose infusion rate during the HIC (GIR)
reﬂects insulin sensitivity mainly in peripheral tissues
because hepatic glucose production is almost completely
suppressed at the high insulin concentration used during
the test [11]. In general, the actual steady-state glucose
concentrations (SSG) and steady-state insulin concentra-
tions (SSI) are different in each patient, although the target
concentrations are set in the glucose clamp tests. The
SSGHGC, SSGHIC, and SSIHIC in this study were 201.7 ±
14.0 mg dl
-1, 92.5 ± 17.4 mg dl
-1, and 112.4 ± 36.1
lUm l
-1, respectively. Because the variation in SSIHIC was
not small and directly affected the estimate of insulin
sensitivity, the GIR revised by the SSI was used as the
estimate of the sensitivity.
The parameter pI4 of the mathematical model was used
as an estimate of second-phase insulin secretion in
response to elevated glucose. During a state of the HGC,
the dI/dt,d G/dt,d RI/dt,d RI1/dt, and dRI2/dt become zero.
By applying these conditions to our model for the insulin
sensitivity index, pI4 is described by the following equation
pI4 ¼
RI
G   Gð0Þ
:
During the HGC, the G - G(0) was assumed to be
constant and the pI4 was proportional to the RI. By doing
this, we could understand that the pI4 had an analogous
meaning to the SSIHGC. In this study, the pG2 was ﬁxed,
and pG3/pG2 was proportional to the pG3. Therefore, the
parameter pG3 was used as an estimate of the insulin
sensitivity of peripheral tissues.
Linear correlation analyses were performed to quantify
thestrengthsofassociationsbetweentwonumericvariables.
Data are expressed as mean ± standard deviations (SD).
Results and discussion
Our OGTT-derived index for the second-phase of insulin
secretion was signiﬁcantly correlated with the steady-state
insulin concentration during the HGC (r = 0.90,
p\0.001, Fig. 3a). Our insulin sensitivity index was sig-
niﬁcantly correlated with the steady-state glucose infusion
rate revised by the insulin concentration (GIR/SSIHIC)
during the HIC (r = 0.56, p\0.001, Fig. 3b).
The average glucose and insulin concentrations during
the OGTTs that served as inputs to the mathematical
models are shown in Fig. 4. The ability of the
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123mathematical models to reproduce the input data was
shown using weighted residuals and the results are shown
in Fig. 5. To obtain the weighted residuals, the residuals
between the results of the model and the input data were
divided by the input values.
These results suggest that our method can potentially
provide an accurate and convenient tool to improve the
management of diabetes in clinical practice by assessing
insulin secretion and insulin sensitivity. Our indices based
on 2-h OGTTs showed good correlation with the analogous
indices obtained from glucose clamp methods. Assessing
these factors using a 2-h OGTT is advantageous because
the 2-h OGTT is widely used for the diagnosis of diabetes
under the WHO criteria, which makes this method easier to
implement in a clinical setting. We compared the estimated
accuracy of our method with that of other previously
reported methods [25, 26] that can be used to assess these
factors using data obtained from a 2-h OGTT. On the basis
of the present data, our method has a higher correlation
coefﬁcient with the glucose clamp than the other approa-
ches (Table 2). Characteristics of these indices in the
subjects are summarized in Table 3.
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Table 2 Correlation coefﬁcients of the OGTT- and clamp-derived
insulin secretion and insulin sensitivity indices [25, 26]
All T2D
SSIHGC
p14 0.90 0.74
p14* 0.83 0.65
HOMA-b 0.67 0.56
II index 0.77 0.53
Insulin0-120 (AUC) 0.80 0.64
GIR/SSIHIC
pG3 0.56 0.60
pG3* 0.51 0.52
HOMA-R 0.42 0.29
QUICKI 0.44 0.36
Matsuda index 0.32 0.30
OGIS120 0.41 0.22
The pI4 * and pG3 * were obtained without pre-processing the OGTT
data. To derive an index of the OGIS120, glucose and insulin
concentrations at 90 min during the OGTT are necessary in addition
to the present input (4 blood samples during the 2-h OGTT) [26].
Here, interpolated G(90) and I(90) were used for the derivation of the
indices
J Physiol Sci (2011) 61:321–330 327
123In a previous study [26], the reproducibility of clinical
indices was assessed with duplicate OGTT data from the
same subjects. The resulting correlation was reported to be
r\0.90. This means that the upper bound of correlation
coefﬁcientsbetweensurrogateindicesandtheglucoseclamp
should be below 0.90. In this context, the present coefﬁcient
of 0.90 between the SSIHGC and pI4 might be too high. Both
inallsubjectsandsubjectswithT2D(Table 2),ourmethod’s
data showed coefﬁcients superior to those from the other
methods, which is an interesting fact regardless of any dis-
cussion about absolute coefﬁcient values.
The use of mathematical modeling may be one reason
why our method showed better estimation accuracy than
the other methods. Multiple factors contribute simulta-
neously to the regulation of glucose metabolism; therefore,
time-dependent dynamics are important to fully understand
the metabolism process. Mathematical modeling using
differential equations is suitable for this type of system
because it can describe the dynamics of a system consisting
of multiple factors.
The pre-processing of the OGTT data may be another
reason for the better estimation accuracy of our method. In
general, the estimation accuracy of a model is enhanced by
using a large amount of input data. However, we limited
the directly available data to four samples from the 2-h
OGTT to enhance the applicability of our method. Then,
we assumed that the information lost by limiting the
samples used could be partially recovered by considering
the following characteristics of glucose and insulin
dynamics: glucose and insulin concentrations change con-
tinuously after the start of the test, the derivative of the
change in these concentrations becomes smaller over time,
and values at 300 min return to the basal level in most
cases [9, 17]. Next, the data were converted to continuous
5-h OGTT data using extrapolation and interpolation, as
described in the parameter estimation section (Fig. 6).
Although clear statistical signiﬁcance cannot be obtained
with the present number of cases, the validity of our
assumption was supported by the estimation accuracy
being improved by this pre-processing to some extent
(Table 1).
Correlation coefﬁcients between the GIR/SSIHIC and the
HOMA-R, QUICKI, and Matsuda indices may seem to be
smaller than those indicated in previous reports [27], but
these coefﬁcients in this study are not exceptionally small.
For instance, correlation coefﬁcients between the glucose
clamp and the HOMA-R have been heterogeneous, ranging
from strong [27] to weak [26]. There is a report which
showed similar coefﬁcients to those in this study [26].
These HOMA-R, QUICKI, and Matsuda indices are based
on the concept that the higher the glucose and insulin
concentrations are, the lower the insulin sensitivity will be.
However, this concept may not be valid for some classes of
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123diabetics who have high glucose concentrations and low
insulin concentrations. In those patients, it is not obvious
that higher insulin concentrations indicate lower insulin
sensitivity. Because the average insulin secretion concen-
trations of the subjects were relatively low (Table 1), this
might be a potential reason for the small correlation
coefﬁcients in this study’s indices.
It should be noted that absolute values of the correlation
coefﬁcients between the OGTT-derived and clamp-derived
indices can often ﬂuctuate and depend on cohorts because
clinical characteristics of the cohorts used for evaluation
can vary greatly. Therefore, there may be differences
between the cohorts but each coefﬁcient can contain
essentially the similar clinical signiﬁcance.
We assumed that the rate of hepatic insulin extraction
was constant and that renal function was normal in building
the model. The model requires insulin secretion to assess
insulin sensitivity using insulin-dependent changes in glu-
cose concentrations. Therefore, our method may have
limitations for those subjects with hepatic dysfunction,
renal impairment, or severe b-cell dysfunction.
Theassessmentofinsulinsecretionandinsulinsensitivity
is of great importance in selecting an optimal diabetic
treatment strategy. The onset and progression of T2D is
strongly correlated with dysfunction of these factors [1].
Most of the agents currentlyused totreat hyperglycemia can
be broadly classiﬁed according to their improvement of one
ofthesefactors[2].Forthisreason,itisimportanttoidentify
the factor that is the underlying cause of the hyperglycemia
so that a targeted therapy can be used. Therefore, the
assessmentofthesefactorsbecomesimportant.Insupportof
this idea, a previous study compared the relationship
between pathologic characterization based on the SSIHGC
and GIR and successful therapy that achieved a well-con-
trolled blood glucose level [28]. In that study, the average
SSIHGC and GIR of patients successfully treated with sul-
fonylurea (glibenclamide) or an insulin sensitizer (pioglit-
azone) were compared. The SSIHGC and GIR in the group
successfullytreatedwithsulfonylureawerelowerthan those
in the group treated with the insulin sensitizer, suggesting
that, for a given therapy to be successful, the medication
should target the underlying cause of the diabetes. This
result demonstrates the importance of the quantitative
assessment of b-cell function and insulin sensitivity for the
selection of a suitable treatment for each patient.
In this study, we have shown that our method is accurate
and potentially applicable in clinical practice for assessing
the diabetic status of an individual patient. One of our goals
is to apply this method to the daily clinical practice of
general practitioners as a tool to determine the optimal
treatment regimen, as do experienced diabetologists.
Although our method showed better correlation coefﬁcients
of the reference values than those obtained by the other
methods, the clinical signiﬁcance of this improvement is
now in question. To validate its clinical signiﬁcance, we
next plan to evaluate our method with additional clinical
data that measures the efﬁcacy of various medications used
to treat hyperglycemia.
Acknowledgments We would like to thank K. Kishi and K. Asano
(Sysmex Corporation, Japan) for their helpful advice and
encouragement.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Kahn SE (2003) The relative contributions of insulin resistance
and beta-cell dysfunction to the pathophysiology of type 2 dia-
betes. Diabetologia 46:3–19
2. Fowler MJ (2007) Diabetes treatment, part 2: oral agents for
glycemic management. Clin Diabetes 25:131–134
3. Mari A (2002) Mathematical modeling in glucose metabolism
and insulin secretion. Assessment of nutritional status and ana-
lytical methods. Curr Opin Clin Nutr Metab Care 5(5):495–501
4. Bergman R, Ider Y, Bowden C, Cobelli C (1979) Quantitative
estimation of insulin sensitivity. Am J Physiol 236(6):E667–E676
0
100
200
300
400
0 60 120 180 240 300
Time (min)
G
l
u
c
o
s
e
 
(
m
g
￿
d
l
-
1
)
,
 
I
n
s
u
l
i
n
 
(
µ
U
￿
m
l
-
1
)
0
100
200
300
400
0 60 120 180 240 300
Time (min)
G
l
u
c
o
s
e
 
(
m
g
￿
d
l
-
1
)
,
 
I
n
s
u
l
i
n
 
(
µ
U
￿
m
l
-
1
) AB Fig. 6 Examples of pre-
processed and parameter-
derived OGTTs. Squares and
triangles represent glucose and
insulin concentrations,
respectively. Dotted lines
represent extrapolated and
interpolated data. Solid lines
represent glucose and insulin
concentrations calculated by the
estimated parameters. a NGT,
b T2D
J Physiol Sci (2011) 61:321–330 329
1235. Toffolo G, Breda E, Cavaghan M, Ehrmann D, Polonsky K,
Cobelli C (2001) Quantitative indexes of beta-cell function dur-
ing graded up&down glucose infusion from C-peptide minimal
models. Am J Physiol Endocrinol Metab 280:E2–E10
6. Steil G, Hwu C, Janowski R, Hariri F, Jinagouda S, Darwin C,
Tadros S, Rebrin K, Saad M (2004) Evaluation of insulin sensi-
tivity and b-cell function indexes obtained from minimal model
analysis of a meal tolerance test. Diabetes 53:1201–1207
7. Dalla Man C, Caumo A, Cobelli C (2002) The oral glucose
minimal model: estimation of insulin sensitivity from a meal test.
IEEE Trans Biomed Eng 49(5):419–429
8. Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C
(2004) Minimal model estimation of glucose absorption and
insulin sensitivity from oral test: validation with a tracer method.
Am J Physiol Endocrinol Metab 287:E637–E643
9. Dalla Man C, Campioni M, Polonsky KS, Basu R, Rizza RA
(2005) Two-hour seven-sample oral glucose tolerance test and
meal protocol: minimal model assessment of b-cell responsivity
and insulin sensitivity in nondiabetic individuals. Diabetes
54:3265–3273
10. Alberti KGMM, Zimmet PZ (1998) Deﬁnition, diagnosis and
classiﬁcation of diabetes mellitus and its complications. Part. 1:
diagnosis and classiﬁcation of diabetes mellitus. Provisional
report of a WHO Consultation. Diabetes Med 15:539–553
11. DeFronzo R, Tobin J, Andres R (1979) Glucose clamp technique:
a method for quantifying insulin secretion and resistance. Am J
Physiol 237(3):E214–E233
12. Campbell PJ, Mandarino LJ, Gerich JE (1988) Quantiﬁcation of
the relative impairment in actions of insulin on hepatic glucose
production and peripheral glucose uptake in non-insulin-depen-
dent diabetes mellitus. Metabolism 37(1):15–21
13. Tamura Y, Niwa M, Uchino H, Uchida T, Kawamori R (2002)
Postprandial hyperglycemia and impaired hepatic glucose uptake
in type 2 diabetes. Int Diabetes Monit 14(2):1–6
14. Ludvik B, Nolan J, Roberts A, Baloga J, Joyce M, Bell J, Olefsky
J (1997) Evidence for decreased splanchnic glucose uptake after
oral glucose administration in non-insulin-dependent diabetes
mellitus. J Clin Invest 100:2354–2361
15. Ishida T, Hosokawa H, Kawanishi K, Irino S (1987) The differ-
ential role of liver and peripheral tissue on glucose metabolism.
In: Shigeta Y, Lebovitz H, Gerich J, Malaisse W (eds) Pro-
ceedings of the 4th Japan–Korea symposium on diabetes mellitus:
best approach to the ideal therapy of diabetes mellitus. Elsevier,
Amsterdam, pp 297–300
16. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T,
Reilly J, Gerich J (1990) Contribution of abnormal muscle and
liver glucose metabolism to postprandial hyperglycemia in
NIDDM. Diabetes 39:1381–1390
17. Dressman JB, Reppas C (eds) (2010) Oral drug absorption: pre-
diction and assessment, 2nd edn. Informa Healthcare, London
18. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R,
Toffolo G, Cobelli C, Rizza R (2006) Pathogenesis of pre-dia-
betes: mechanisms of fasting and postprandial hyperglycemia in
people with impaired fasting glucose and/or impaired glucose
tolerance. Diabetes 55:3536–3549
19. Vapnik V, Golowich S, Smola AJ (1997) A support vector
method for function approximation, regression estimation, and
signal processing. In: Mozer MC, Jordan MI, Petsche T (eds)
Advances in neural information processing systems: proceedings
of the 1996 conference on neural information processing systems,
vol 9. MIT Press, Cambridge, pp 281–287
20. Lu J, Seike M, Liu W, Wu P, Wang L, Wu Y, Naito Y, Nakajima
H, Kouchi Y (2009) Extrapolation of clinical data from an oral
glucose tolerance test using a support vector machine. World
Acad Sci Eng Technol 53:1271–1274
21. Fritsch FN, Carlson RE (1980) Monotone piecewise cubic
interpolation. SIAM J Numer Anal 17:238–246
22. Kahaner D, Moler C, Nash S (1989) Numerical methods and
software. Prentice-Hall, Englewood Cliffs
23. Carson ER, Cobelli C, Finkelstein L (1983) The mathematical
modeling of metabolic and endocrine systems. Wiley, New York
24. Toffolo G, Campioni M, Basu R, Rizza RA, Cobelli C (2006) A
minimal model of insulin secretion and kinetics to assess hepatic
insulin extraction. Am J Physiol Endocrinol Metab 290:E169–
E176
25. Pacini G, Mari A (2003) Methods for clinical assessment of
insulin sensitivity and b-cell function. Best Pract Res Clin
Endocrinol Metab 17(3):305–322
26. Mari A, Ludvik B, Pacini G, Nolan JJ, Murphy E (2001) A
model-based method for assessing insulin sensitivity from the
oral glucose tolerance test. Diabetes Care 24:539–548
27. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F,
Zenere MB, Monauni T, Muggeo M (2000) Homeostasis model
assessment closely mirrors the glucose clamp technique in the
assessment of insulin sensitivity: studies in subjects with various
degrees of glucose tolerance and insulin sensitivity. Diabetes
Care 23:57–63
28. Gorogawa S, Kaneto H, Matsuhisa M, Ohtoshi K, Kawamori D,
Hazama Y, Yoshiuchi K, Yamasaki Y (2005) Possible novel
index determined by the glucose clamp test for selection of a
suitable therapy for each type 2 diabetic patient. Diabetes Res
Clin Pract 69(1):1–4
330 J Physiol Sci (2011) 61:321–330
123